Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 8/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CCNK | O75909 | 2/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300220 | 0.86 | CDK2 (0.46) | CDK2MAPKAPK2CHEK1CCNT1CCNK | |
| SCHEMBL3300233 | 0.86 | CDK2 (0.46) | CDK2MAPKAPK2CHEK1CCNT1CCNK | |
| Hydrochloric Acid SCHEMBL3303920 | 0.76 | MAPKAPK2 (0.39) | CDK2MAPKAPK2CHEK2 | |
| SCHEMBL3303037 | 0.75 | EGLN2 (0.42) | CDK2GRM5 | |
| SCHEMBL3304389 | 0.71 | EGLN2 (0.48) | GRM5 | |
| SCHEMBL3303060 | 0.71 | IDH2 (0.48) | CDK2MAPKAPK2CHEK1CCNT1CDK9 | |
| SCHEMBL3299720 | 0.71 | IDH2 (0.48) | CDK2MAPKAPK2CHEK1CCNT1CDK9 | |
| SCHEMBL13392304 | 0.68 | IDH2 (0.45) | CDK2MAPKAPK2CCNT1CDK9IDH2 | |
| SCHEMBL3309911 | 0.68 | KMT2A (0.43) | — | |
| SCHEMBL2145075 | 0.68 | EGLN2 (0.40) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | CDK2 37/4885MAPKAPK2 23/4885CHEK1 44/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | CDK2 37/4885MAPKAPK2 23/4885CHEK1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.